Biohit Oyj - Company Announcement

Biohit Oyj B-shares Subscribed with Stock Options I and II 2013

Biohit Oyj Stock Exchange Release June 12, 2014 at 10:40 a.m.  (EEST)


A total number  of 160,000 new Biohit Oyj B-shares have been subscribed for
with stock options I 2013 ja II 2013 during May 21 - June 2,  2014. These
shares have been entered into the trade register on June 12, 2014, as of which
date the new shares will establish equal shareholder rights with the company's
existing B-shares. Public trading is expected to begin on NASDAQ OMX Helsinki
as of June 13, 2014 together with the existing B-shares. 

The share subscription price was EUR 2.2766 per share with stock options I 2013
and II 2013. The entire subscription price of EUR 364,256 will be credited to
the reserve for invested non-restricted equity, and the company share capital
remains unchanged. The shares have no nominal value. 

After the subscription the number of all Biohit Oyj's shares will rise into
13,985,593 shares (13,825,593) and B-shares will rise into 11,010,093 shares
(10,850,093). The new shares will correspond to a percentage of 1.1% of Biohit
Oyj's total number of shares and 0.23% of the voting rights after registration. 

The share subscription period with stock options I 2013A began on June 1, 2014
and all the available 100,000 shares were subscribed. The share subscription
period with stock options II 2013 began on July 1, 2013 and will end June 30,
2015. The option schemes are based on the Biohit Oyj board resolution of June
19, 2013 and the Annual General Meeting authorization of April 13, 2011. The
terms and conditions of the option schemes with additional information are
available on Biohit Oyj website at www.biohithealthcare.com. 


Additional information:

CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com


Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit's
mission is “Innovating for Health” - we produce innovative products and
services to promote research and early diagnosis. Biohit is headquartered in
Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B
share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare
group. www.biohithealthcare.com